Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Feb 2, 2021 at 8:00 AM EST
Aug 25, 2020 at 8:30 AM EDT
Mar 30, 2020 at 8:30 AM EDT